Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

M. Kawamura



Author of

  • +

    P2.06 - Poster Session 2 - Prognostic and Predictive Biomarkers (ID 165)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Biology
    • Presentations: 1
    • +

      P2.06-018 - Correlation of TS mRNA expression level and TS protein level detected by immunostaining for use in post-operative primary lung cancer therapy (ID 1697)

      09:30 - 09:30  |  Author(s): M. Kawamura

      • Abstract

      Background
      There has been a focus on the use of thymidylate synthase (TS) as a biomarker for the long term administration of metabolic antagonists for lung cancer. TS mRNA levels have been measured by real time RT-PCR in tumors collected using a micro-dissection method; however, this method has not been applicable for general use and its clinical use has been problematic. Therefore, this study investigated the correlation of TS mRNA expression level and a commonly used semiquantitative immunohistochemical method.

      Methods
      Resected lung specimens were collected from 47 patients with Stage IA (T1b) and IIB primary non-small-cell lung cancer who had undergone lobectomy between 2006 and 2012 at our Hospital. Levels of mRNA expression were measured using the Danenberg Tumor Profile method while TS immunostaining with anti-TS mouse IgG MoAB was graded into 4 levels.

      Results
      Of 47 patients, 24 patients were male and 23 patients were female. Thirty six people had adenocarcinoma while 11 patients exhibited squamous cell carcinoma. The number of patients at each IA, IB, IIA and IIB stage were 20, 20, 5, and 2, respectively. TS mRNA expression levels of these patients were between 0.69 and 12.68 (a median value of 2.47). Immunostaining indicated that Grade 0, 1, 2, and 3 were observed in 3, 17, 15 and 12, respectively. A moderate positive correlation was observed at a correlation coefficient of r=0.4880 between mRNA expression levels and immunostain levels (A). Moreover, a significant correlation between mRNA expression levels and immunostain levels was observed when mRNA expression levels were divided into two groups, one with higher than median values and the other with lower than median values, where Grade 0 and 1 were assigned as negatively stained and Grade 2 and 3 were assigned as positively stained (B).Figure 1

      Conclusion
      Immunostaining is a useful method for measuring TS level when TS is being considered as an appropriate biomarker for postoperative adjuvant chemotherapy with 5-FU delivertives.

  • +

    P2.12 - Poster Session 2 - NSCLC Early Stage (ID 205)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P2.12-004 - Percutaneous cryoablation for the treatment of inoperable stage I non-small cell lung cancer: mid-term outcome (ID 997)

      09:30 - 09:30  |  Author(s): M. Kawamura

      • Abstract

      Background
      To evaluate the midterm results of percutaneous cryoablation for medically inoperable stage I non-small cell lung cancer.

      Methods
      Between January 2004 and June 2010, 160 patients underwent computer tomography guided percutaneous cryoablation for lung tumors at our institution. Of these patients, histologically proven stage I primary lung cancer patients with more than one year of follow-up, were retrospectively reviewed. All of these patients were considered to be medically inoperable. Follow-up was based primarily on computed tomography.

      Results
      There were 22 patients with 34 carcinoma who underwent 25 sessions of cryoablation treatment. Complications were pneumothoraces in 7 treatments (28%, chest tube required in one treatment), and pleural effusions in 8 treatments (31%). The observation period ranged from 12 to 92 months, average 44±22 months, median 38 months. Local tumor progression was observed in two carcinomas (3%). Mean local disease progression-free interval was 88±8 months. Median local disease progression-free interval was not achieved. The overall 3-year survivals were 90.7%. Mean overall survival was 88±8 months. Median overall survival was not achieved. The disease-specific 3-year survivals were 100%. Mean overall survival was 81±14 months. Median overall survival was not achieved. The disease-free 3-year survivals were 77%. Mean disease-free survival was 64±19 months. Median disease-free survival was 89 month. Pulmonary function tests were done in 16 patients (18 treatments) before and more than 3 months after cryoablation. Percentage of predicted vital capacity, and percentage of predicted forced expiratory volume in 1 second, did not differ significantly before and after cryoablation (93±23 versus 90±21, and 70±11 versus 70±12, respectively).

      Conclusion
      Although further accumulation of data is necessary regarding efficacy, cryoablation may be a feasible option in inoperable stage I primary lung cancer patients.